These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 31335691

  • 1. Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma.
    Amrane K, Le Goupil D, Quere G, Delcroix O, Gouva S, Schick U, Salaun PY, Abgral R, Alavi Z, Keromnes N, Querellou S.
    Medicine (Baltimore); 2019 Jul; 98(29):e16417. PubMed ID: 31335691
    [Abstract] [Full Text] [Related]

  • 2. The utility of 68F-FDG PET/CT for evaluation of tumor response to immune checkpoint inhibitor therapy and prognosis prediction in patients with non-small-cell lung cancer.
    Kitajima K, Kawanaka Y, Komoto H, Minami T, Yokoi T, Kuribayashi K, Kijima T, Nakamura A, Hashimoto M, Kondo N, Hasegawa S, Yamakado K.
    Hell J Nucl Med; 2021 Jul; 24(3):186-198. PubMed ID: 34901959
    [Abstract] [Full Text] [Related]

  • 3. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using 18F-FDG PET/CT: multicenter study for comparison of EORTC, PERCIST, and imPERCIST.
    Kitajima K, Watabe T, Nakajo M, Ishibashi M, Daisaki H, Soeda F, Tanemura A, Kanekura T, Yamazaki N, Ito K.
    Jpn J Radiol; 2022 Jan; 40(1):75-85. PubMed ID: 34287739
    [Abstract] [Full Text] [Related]

  • 4. Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.
    Kitajima K, Kuribayashi K, Minami T, Yokoyama H, Nakamura A, Hashimoto M, Kijima T, Hasegawa S, Kaida H, Yamakado K.
    Oncotarget; 2024 Jun 20; 15():408-417. PubMed ID: 38900646
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. 18F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma.
    Ito K, Teng R, Schöder H, Humm JL, Ni A, Michaud L, Nakajima R, Yamashita R, Wolchok JD, Weber WA.
    J Nucl Med; 2019 Mar 20; 60(3):335-341. PubMed ID: 30413661
    [Abstract] [Full Text] [Related]

  • 12. The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma.
    Sachpekidis C, Anwar H, Winkler J, Kopp-Schneider A, Larribere L, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A.
    Eur J Nucl Med Mol Imaging; 2018 Jul 20; 45(8):1289-1296. PubMed ID: 29478079
    [Abstract] [Full Text] [Related]

  • 13. FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment.
    Iravani A, Osman MM, Weppler AM, Wallace R, Galligan A, Lasocki A, Hunter MO, Akhurst T, Hofman MS, Lau PKH, Kee D, Au-Yeung G, Sandhu S, Hicks RJ.
    Eur J Nucl Med Mol Imaging; 2020 Nov 20; 47(12):2776-2786. PubMed ID: 32338306
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. 18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab.
    Sachpekidis C, Kopp-Schneider A, Hakim-Meibodi L, Dimitrakopoulou-Strauss A, Hassel JC.
    Melanoma Res; 2019 Apr 20; 29(2):178-186. PubMed ID: 30653029
    [Abstract] [Full Text] [Related]

  • 16. Comparison of 18F-FDG PET/CT Criteria for the Prediction of Therapy Response and Clinical Outcome in Patients With Metastatic Melanoma Treated With Ipilimumab and PD-1 Inhibitors.
    Annovazzi A, Vari S, Giannarelli D, Pasqualoni R, Sciuto R, Carpano S, Cognetti F, Ferraresi V.
    Clin Nucl Med; 2020 Mar 20; 45(3):187-194. PubMed ID: 31977479
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma.
    Sachpekidis C, Kopp-Schneider A, Pan L, Papamichail D, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A.
    Eur J Nucl Med Mol Imaging; 2021 Jun 20; 48(6):1932-1943. PubMed ID: 33336264
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.